report solid revenu top preliminari report
beat origin forecast revenu guidanc
reiter gross margin rang oper
spend expect higher includ anoth
invest market non-intens therapi
commentari competit continu posit emphas swell
referr potenti new patient competitor spread word
continu glucos monitor cgm seem
pressur due factori buildout anticip price pressur
may pressur share season link insur deduct
expect impact sale usual
strong explan expect slowdown growth
suspect could conservat
remain neutral feel new competit put pressur
price take user also expand market
competit heat note posit volum trend
increas patient awar cgm seem focu
price marketplac think pressur intensifi
platform fda hope launch
platform believ approv need
calibr would big win patient may give new
product battl competitor match calibr
put ad focu non-intens market
includ collabor verili type dispos cgm
goal launch type pilot program
unitedhealthcar compani expect spend
invest year type market opportun
larg expect focu timelin draw nearer
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
report revenu slightli pre-announce preliminari revenu
forecast gross margin bp better estim
overal oper spend also model driven lower sg
spend put take led five cent beat adjust ep
reduc revenu outlook reflect guidanc
commentari forecast includ lower price transmitt
receiv slight reduct averag number sensor kit order
per quarter model revenu y/i growth
sensor volum grow intern sale grow patient
base increas
lower gross margin within guidanc rang
year also tweak model recoveri
reduc oper expens slightli reflect guidanc
growth addit spend non-intens program
chang result signific reduct lp forecast
smaller reduct ep project
actualsbtig estimate variancetot revenu net incom spend spend opex spend btig estim compani filingsvari
rate neutral believ current multipl
estim ntm ev/sal reason feel share trade
quarterli beat miss think investor want see growth
re-ent stori concern competit
increas spend risk rate includ competit increas
spend chang revenu growth rate fda product recal
reimburs price pressur
bpsebit bpssourc btig estim compani filingsnewold chang
incom product develop grant oper expens tax expens net incom share net incom net incom analysisgross profit net incom revenu oper oper btig estim compani report
revenu eworldwid patient basebegin new drop patient re-ord disclos histor patient price revenu re-ord disclos histor patient price revenu hardwar revenu sensor kit order per quarter disclos histor per sensor revenu product btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
